Danish Economy Gets Boost from Novo Nordisk's Success Abroad

Danish central bank raised economic growth forecast through 2025 due to success of drugmakers like Novo Nordisk
Novo Nordisk's growth abroad boosts Denmark's GDP as production happens under Danish ownership
Bank says growth seems driven by production in small pharmaceutical segment, largely abroad
Without pharmaceutical industry contribution, economy would have contracted in first half of 2023
House prices and inflation forecasts lowered compared to previous estimates

yahoo.com

Relevant topic timeline:

8/21/2023

How soaring demand for Ozempic and Wegovy is altering Denmark's economy

The success of weight-loss drugs in the United States, particularly Novo Nordisk's Wegovy and Ozempic, has led to a surge in sales and profits, driving an influx of US dollars into Denmark's economy and boosting the value of the Danish krone. As a result, Denmark's central bank is keeping interest rates low, leading to lower mortgage rates for Danish homeowners.

9/1/2023

Nomura, Morgan Stanley raise India's fiscal 2024 economic growth forecast, Bank of America cuts

Economists at Nomura and Morgan Stanley raise their growth forecast for India's fiscal 2024 after the economy grew at its fastest pace in a year in the April-June quarter, while BofA Global Research cuts their estimates as quarterly growth falls below their forecast.

9/6/2023

Denmark's economy boosted by anti-obesity treatments

The Danish pharmaceutical company Novo Nordisk is driving the country's economic growth, with its profits and production of anti-obesity drugs contributing significantly to the GDP and employment rates.

10/3/2023

World Bank Upgrades Sri Lanka Growth Forecast But Warns of Risks Ahead

The World Bank has raised its forecasts for Sri Lanka's economy, expecting growth of 1.7% in 2024 and a smaller contraction of 3.8% this year, citing progress in reducing inflation and increased tourism revenue, but also cautioning about significant uncertainty and downside risks.

10/13/2023

Novo Nordisk Raises 2022 Outlook for Third Time as Wegovy and Ozempic Demand Soars in U.S.

Novo Nordisk has raised its full-year sales and operating profit outlook for the third time this year due to strong demand for its weight-loss drug Wegovy and diabetes medication Ozempic in the United States, leading to a record-high in its shares.

Topics

Posted 9/20/2023, 2:23:18 PM